BridgeBio Pharma (BBIO) Free Cash Flow (2018 - 2026)

BridgeBio Pharma has disclosed Free Cash Flow across 9 years of filings, most recently posting -$197.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$197.3 million, up 1.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$444.8 million (up 11.33% YoY), and the FY2025 annual result was -$447.0 million, up 14.31% from the prior year.
• Free Cash Flow came in at -$197.3 million for Q1 2026 at BridgeBio Pharma, down from -$57.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $74.7 million in Q2 2024 to a low of -$219.6 million in Q1 2024.
• The 5-year median for Free Cash Flow is -$135.2 million (2022), against an average of -$124.4 million.
• Across the five-year window, Free Cash Flow sank 282.49% in 2023 and jumped 165.83% in 2024, its largest moves.
• BridgeBio Pharma's Free Cash Flow stood at -$93.2 million in 2022, then sank by 34.35% to -$125.3 million in 2023, then slumped by 55.98% to -$195.4 million in 2024, then soared by 70.57% to -$57.5 million in 2025, then slumped by 243.18% to -$197.3 million in 2026.
• The last three Free Cash Flow figures came in at -$197.3 million (Q1 2026), -$57.5 million (Q4 2025), and -$109.0 million (Q3 2025), per Business Quant data.